EW Q3 2024 Earnings — Edwards Lifesciences Corporation Revenue & Financial Results | Market Cap Arena

EWEdwards Lifesciences Corporation

$50B

Q3 2024 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$1.4B+8.9% YoY

Gross Profit

$1.1B80.6% margin

Operating Income

$351M25.9% margin

Net Income

$3.1B226.7% margin

EPS (Diluted)

$5.13

QoQ Revenue Growth

-2.3%

Cash Flow

Operating Cash Flow

$352M

Free Cash Flow

$320M

Stock-Based Comp.

$42M

Balance Sheet

Total Assets

$13.0B

Total Liabilities

$3.4B

Stockholders' Equity

$9.5B

Cash & Equivalents

$3.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.4B	$1.2B	+8.9%
Gross Profit	$1.1B	$971M	+12.4%
Operating Income	$351M	$347M	+1.2%
Net Income	$3.1B	$385M	+697.8%

Revenue Segments

Transcatheter Heart Valves

$1.0B76%

Surgical Heart Valve Therapy

$240M18%

Transcatheter Mitral And Tricuspid Therapies

$91M7%

Geographic Segments

UNITED STATES

$805M59%

Europe

$320M24%

Rest of World

$149M11%

JAPAN

$81M6%